Efficacy of a ML336 derivative against Venezuelan and eastern equine encephalitis viruses.

ABSTRACT: Currently, there are no licensed human vaccines or antivirals for treatment of or prevention from infection with encephalitic alphaviruses. Because epidemics are sporadic and unpredictable, and endemic disease is common but rarely diagnosed, it is difficult to identify all populations requiring vaccination; thus, an effective post-exposure treatment method is needed to interrupt ongoing outbreaks. To address this public health need, we have continued development of ML336 to deliver a molecule with prophylactic and therapeutic potential that could be relevant for use in natural epidemics or deliberate release scenario for Venezuelan equine encephalitis virus (VEEV). We report findings from in vitro assessments of four analogs of ML336, and in vivo screening of three of these new derivatives

SUBMITTER: Jonsson CB 

PROVIDER: S-EPMC7305796 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature